Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 9, 2007

Innogenetics’ Permanent Injunction Against Abbott Upheld

  • The U.S. Court of Appeals denied Abbott Laboratories' motion for a stay of injunction in favor of Innogenetics regarding the willful infringement of Innogenetics patented hepatitis C virus genotyping technology.

    A January 10, 2007 ruling by the U.S. District Court for the Western District of Wisconsin permanently prevented Abbott from any further sales, use, or export of products that infringe on Innogenetics' patent and awarded $7 million in damages. Abbott then filed an emergency motion to stay the injunction pending its appeal. On January 19, the Federal Circuit temporarily stayed the injunction while it considered Abbott's motion.

    "Yesterday's decision marks a positive first step in the appeal process and reinforces our belief that we will prevail in the Court of Appeals, just as we did at trial," says Frank Morich, CEO of Innogenetics.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »